Voya Investment Management LLC Makes New Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Voya Investment Management LLC purchased a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 29,670 shares of the company's stock, valued at approximately $497,000.

Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after purchasing an additional 660 shares during the period. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the period. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares during the period. Finally, Franklin Resources Inc. grew its stake in Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after acquiring an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $12.29 on Friday. The business's 50-day simple moving average is $13.86 and its 200-day simple moving average is $15.67. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -8.03 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. As a group, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the transaction, the insider now directly owns 134,021 shares of the company's stock, valued at $2,189,903.14. The trade was a 6.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David M. Chao sold 7,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares of the company's stock, valued at $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 171,827 shares of company stock valued at $2,705,568 in the last quarter. Insiders own 11.59% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on CNTA shares. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $30.00 target price for the company. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a report on Thursday. They set an "outperform" rating and a $6.00 price objective for the company. Morgan Stanley restated an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $27.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.